Interpace Biosciences, Inc. Common Stock
IDXG
IDXG was delisted on the 24th of February, 2021.
18 hedge funds and large institutions have $2.14M invested in Interpace Biosciences, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
41% more capital invested
Capital invested by funds: $1.52M → $2.14M (+$625K)
29% more funds holding
Funds holding: 14 → 18 (+4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$1.29M |
| 2 |
MFG
Magnus Financial Group
New York
|
+$220K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$157K |
| 4 |
Squarepoint
New York
|
+$114K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$58.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$190K |
| 2 |
VF
Virtu Financial
New York
|
-$55K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$7K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$4.5K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$5 |
IDXG Hedge Fund Activity: Q3 2020 in Review
18 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Interpace Biosciences, Inc. Common Stock (IDXG) for Q3 2020, worth a combined $2.14M — up 41% from $1.52M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new IDXG positions and 3 closed out — a net gain of 4 holders — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $1.29M. The largest seller was Essex Investment Management, exiting entirely with an estimated $190K sold.
- 18 institutional investors held Interpace Biosciences, Inc. Common Stock (IDXG) as of Q3 2020, up from 14 in Q2 2020.
- Funds reported $2.14M of Interpace Biosciences, Inc. Common Stock stock for Q3 2020, up 41% quarter-over-quarter.
- 7 funds opened new Interpace Biosciences, Inc. Common Stock positions in Q3 2020 and 3 closed out, a net change of +4 holders.
- The largest Interpace Biosciences, Inc. Common Stock buyer in Q3 2020 was Stonepine Capital Management, an estimated $1.29M added.
- The largest Interpace Biosciences, Inc. Common Stock seller in Q3 2020 was Essex Investment Management, an estimated $190K sold.
Based on aggregated 13F filings for Q3 2020.